Inhibition of WNT, TGF beta and Hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders

摘要

Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of:; wherein each of R¹-R⁵ is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hydroxy, or amino; and R⁶ is selected from H, optionally substituted alkyl, or optionally substituted aryl.